Petrie, M., Solomon, S., Claggett, B. L., Jering, K., Steg, G., Granger, C., … Pfeffer, M. A. (2022). PARADISE-MI - event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40. In EUROPEAN HEART JOURNAL (Vol. 43, pp. 1449–1449).

Petrie, M., S. Solomon, B. L. Claggett, K. Jering, G. Steg, C. Granger, E. Lewis, et al. “PARADISE-MI - event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40.” In EUROPEAN HEART JOURNAL, 43:1449–1449, 2022.

Petrie M, Solomon S, Claggett BL, Jering K, Steg G, Granger C, et al. PARADISE-MI - event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40. In: EUROPEAN HEART JOURNAL. 2022. p. 1449–1449.

Petrie, M., et al. “PARADISE-MI - event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40.” EUROPEAN HEART JOURNAL, vol. 43, 2022, pp. 1449–1449.

Petrie M, Solomon S, Claggett BL, Jering K, Steg G, Granger C, Lewis E, Kober L, Mann D, Rouleau JL, McMurray JJ, Maggioni A, Braunwald E, Pfeffer MA. PARADISE-MI - event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40. EUROPEAN HEART JOURNAL. 2022. p. 1449–1449.